Enrolment complete for venous leg ulcer healing product
This article was originally published in Clinica
Executive Summary
New York firm Ortec International has completed patient enrolment for its confirmatory trial for the use of cryopreserved OrCel - a regenerative product for chronic wounds - to treat venous leg ulcers. The firm hopes to validate results from its pivotal trial, where 59% of patients treated with cryopreserved OrCel achieved wound closure, compared with 36% of patients receiving standard care. OrCel is composed of a collagen sponge containing cells that secrete growth factors and cytokines normally found in acute wounds. Ortec hopes to submit a PMA application to the FDA by mid July 2006, after the 12-week treatment phase is completed.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.